From: Robustness of sepsis-3 criteria in critically ill patients
 | N | Sepsis-3 incidence, % (95%CI) | MARS-sepsis incidence, % (95%CI) | Agreement (%) | p value a | Sepsis-3 mortality, % (95%CI) b | MARS-sepsis mortality, % (95%CI) b | p value a |
Complete cohort | 1582 | Â | Â | Â | Â | Â | Â | Â |
▪ Infection at admission | 1081 | 90 (88–92) | 60 (57–63) | 64 | < 0.001 | 28 (26–31) | 36. (33–40) | < 0.001 |
▪ ICU-acquired infection | 501 | 52 (48–56) | 54 (50–58) | 58 | 0.49 | 40 (34–46) | 45 (39–51) | < 0.001 |
Probable infection cohort c | 1304 | Â | Â | Â | Â | Â | Â | Â |
▪ Infection at admission c | 971 | 90 (88–92) | 61 (58–64) | 65 | < 0.001 | 29 (26–32) | 37 (33–41) | < 0.001 |
▪ ICU-acquired infection c | 334 | 53 (48–59) | 56 (51–62) | 59 | 0.39 | 44 (37–51) | 51 (42–56) | < 0.001 |
 |  | Septic shock-3 incidence, % (95%CI) a | MARS-shock incidence, % (95%CI) a | Agreement (%) | p value | Septic shock-3 mortality, % (95%CI) b | MARS-shock mortality, % (95%CI) b |  |
N | Â | Â | Â | Â | Â | Â | Â | |
Complete cohort | 1582 | Â | Â | Â | Â | Â | Â | Â |
▪ Infection at admission | 1081 | 38 (35–41) | 27 (24–30) | 80 | < 0.001 | 41 (36–46) | 50 (45–56) | < 0.001 |
▪ ICU-acquired infection | 501 | 18 (15–21) | 19 (16–23) | 81 | 0.47 | 57 (47–67) | 69 (59–78) | < 0.001 |
Probable infection cohort c | 1304 | Â | Â | Â | Â | Â | Â | Â |
▪ Infection at admission c | 971 | 39(36–42) | 28 (25–31) | 79 | < 0.001 | 42 (37–47) | 51 (46–57) | < 0.001 |
▪ ICU-acquired infection c | 334 | 19 (15–23) | 22 (18–27) | 83 | 0.11 | 63 (50–74) | 73 (62–82) | < 0.001 |